Transcriptomic profile of patient derived glioblastoma stem cells from recurrent and newly diagnosed background

Metabolic rewiring of neoplastic cells can fuel tumorigenicity of cancer stem cells contributing to tumor recurrence. One such cancer is glioblastoma for which tumor recurrence is universal. After first line therapy includes surgical resection, temozolomide chemotherapy, and radiotherapy. Tumorigenic fueling of glioblastoma stem cells (GSCs) which have invaded into distal brain parenchyma that are unresectable and/or resistant to standard chemo and radiation therapy promote recurrence. We wanted to focus on studying whether there is a correlaion between metabolic substrate utilization, stemness, and tumorigenicity of patient derived GSC populations. Leveraging the knowledge of metabolic substrate utilization by the GSCs and their stemness potential may be a promissory target to curb the aggressiveness of the GSCs. Thus we embark on a journey to investigate the transcriptomic profile of the patient derived GSCs from varied background. Considering the heterogeneity of the GSCs, it is of utmost important to study patient derived GSCs from varied bakground. Our pool of cells comprise of 2 recurrent patient derived GSCs and 2 newly diagnosed GSCs. Our long term goal being to design and develop alternative nanotherpaeutic approaches to target the otherwise hard-to-target GSCs in the brain, we concentrated on using patient derived cells to closely recapitulate the tumor characteristics whiich would have been difficult if conventional cell lines were used. Thereby, a complete understanding of the genomic profile of the GSCs from varied patient background would help us figure out the best possible target site for therpeutics against GSCs and as a result delay/stop the tumor recurrence.